

Tissue Model of the Epithelial Mesenchymal Trophic Unit

TEAM: CARLEY SCHWARTZ, ELIJAH DIEDERICH, CAITRÍONA TREACY, WILL ONUSCHECK, ANURAAG SHREEKANTH BELAVADI, NICK HERBST

CLIENT: DR. ALLAN BRASIER

ADVISOR: PROF. TRACY JANE PUCCINELLI

SPRING 2024 POSTER PRESENTATION 04/26/2024

ACKNOWLEDGEMENTS: THE TEAM THANKS PROF. TJ PUCCINELLI, THE MEMBERS OF THE BRASIER LAB, AND DR. JOHN PUCCINELLI



PROBLEM STATEMENT

- Lack of scaffolds that model the lung ECM and its changes due to cell injury from diseases (like COPD & pulmonary fibrosis)
- Dr. Brasier of the UWSMPH needs such a scaffold
 - Provide him with a tool to study lung inflammation and disease
 - Would aid in translational research such as therapies that target lung tissue changes induced by diseased state
 - Scaffold must be bioprinted

SMALL AIRWAY ECM

- The extracellular matrix (ECM) is a network of proteins and macromolecules [1]
 - Provides support and mechanical/biochemical cues to cells
- The epithelial mesenchymal trophic unit (EMTU) is made of [1]:
 - Lung epithelial cells, surrounding ECM, subepithelial fibroblasts
- Chronic lung diseases injure lung epithelium [2]
 - Inflammatory response increases fibroblast activity
 - Fibroblasts produce more proteins such as collagen and fibronectin
 - The mechanical stiffness of the ECM increases




Figure 1: Schematic of EMTU response to injury [2]

CLINICAL SIGNIFICANCE

- COPD is 3rd leading cause of death in the world [3]
- In the US, over 120,000 people die yearly of COPD [4]
- While not curable, current COPD treatments include:
 - Bronchodilators (inhalers) which relax and open the airways
 - Oral steroid medications
 - Pulmonary rehabilitation
 - Surgery (severe cases) [3]
- Tissue model would contribute to more thorough understanding of diseases and development of individualized treatments




Figure 2: Graphic depicting the effects of COPD on the lungs [5]

DESIGN CRITERIA

- Tunable mechanical stiffness
 - Healthy tissue: 2-5 kPa
 - Fibrotic tissue: ≥ 16.5 kPa
- Mimics biochemical properties of native lung ECM
 - Cell adhesive and enzymatically degradable for remodelling
- Support co-culture of fibroblasts and human small airway epithelial cells (hSAECs)
- <12 mm diameter to be compatible with an air-liquid interface (ALI)

FINAL DESIGN

- **Biomaterial:** Gelatin Methacryloyl (GelMA)
 - **Pipette-based hydrogels**
 - 50% degree of functionalization
 - Cylindrical molds
 - 9 mm diameter
 - 365 nm UV light
 - 5 min for healthy stiffness
 - 15 min for fibrotic stiffness
 - **Bioprinted hydrogels**
 - CELLINK GelMA bioink w/ 0.25% LAP photoinitiator [6]
 - 3D cylindrical structure
 - 10 mm diameter x 2 mm thickness
 - Heating Temperature: 37 °C
 - Equilibrium Time: 30 min
 - Infill Density: 52%
 - Printing Temperature: 26.1 °C
 - Extrusion Pressure: 40 kPa
 - 405 nm UV light
 - 2 s for healthy stiffness
 - 13 s for fibrotic stiffness




Figure 3: Bioprinted GelMA hydrogels



Figure 4: CELLINK BioX 3D Bioprinter [6]

RHEOMETRY

- Mechanical stiffness of bioprinted hydrogels assessed via converting rheometry-obtained shear moduli (G) to Young's moduli (E)
 - $E = 2G(1+\nu)$
 - $\nu = 0.5$ for hydrogels [7]
- Frequency-sweep
 - Strain control - 1%
 - 0.1 Hz - 10 Hz

Condition (UV time)	Stiffness (kPa)
Healthy (2 s)	4.82 ± 0.6
Semi-Stiff (10 s)	12.31 ± 2.8
Fibrotic (13 s)	18.52 ± 3.6

Figure 5: Gels were swelled in cell culture media for 24 hr prior to testing

CELL VIABILITY

- Encapsulated fibroblasts in pipette-based hydrogels to assess GelMA's ability to support cells
- Bright-field images show fibroblastic morphology
- LIVE/DEAD™ staining and imaging of cell-laden gels at four time points
- % cell viability after 1 week:
 - Healthy stiffness: $86.7 \pm 6.7\%$
 - Fibrotic stiffness: $85.1 \pm 7.5\%$




Figure 6: Representative bright-field and fluorescence images of cell-laden hydrogels




Figure 7: Plot of % cell viability for healthy and fibrotic stiffness hydrogels over time

FUTURE WORK

- hSAEC seeding on top of hydrogels to evaluate cell adherence
- Fibroblast/hSAEC co-culture (w/ cell viability testing)
- Incorporation of fibroblasts into bioink for bioprinting

REFERENCES

1. E. S. White, "Lung Extracellular Matrix and Fibroblast Function," *Ann Am Thorac Soc*, vol. 12, no. Suppl 1, pp. S30–S33, Mar. 2015, doi: 10.1513/AnnalsATS.201406-240MG.
2. A. R. Brasier, D. Qiao, and Y. Zhao, "The hexosamine biosynthetic pathway links innate inflammation with epithelial-mesenchymal plasticity in airway remodeling," *Frontiers in Pharmacology*, vol. 12, Dec. 2021.
3. "Chronic obstructive pulmonary disease (COPD)." Accessed: Dec. 06, 2023. [Online].
4. "Treating chronic obstructive pulmonary disease." McKesson Medical-Surgical, [Online].
5. W.W. LaMorte, "Chronic obstructive pulmonary disease (COPD)," *Respiratory Health*, [Online].
6. CELLINK, "GelMA Bioink LAP 0.25%," *CELLINK*. Accessed: Sep. 29, 2023. [Online].
7. Y. Javanmardi, H. Colin-York, N. Szita, M. Fritzsche, and E. Moenendarbary, "Quantifying cell-generated forces: Poisson's ratio matters," *Commun Phys*, vol. 4, no. 1, pp. 1–10, Nov. 2021, doi: 10.1038/s42005-021-00740-y.